Fact-checked by Grok 2 weeks ago

Lethal dose

The lethal dose (LD), most commonly expressed as the median lethal dose or LD50, quantifies the amount of a substance, such as a chemical, drug, or radiation, that causes death in 50% of a tested population, usually rodents, when administered via a specified route like oral, dermal, or inhalation. This metric, derived empirically from dose-response experiments plotting mortality against exposure levels, enables standardized comparisons of acute toxicity across substances and serves as a foundational tool in toxicology for establishing safety thresholds, regulatory classifications, and therapeutic indices in pharmacology. Introduced by British pharmacologist John William Trevan in 1927 to address inconsistencies in early toxicity assessments that relied on vague "minimal lethal doses," the LD50 shifted evaluation toward probabilistic, data-driven estimates, often calculated using statistical methods like probit analysis on groups of 10–50 animals per dose level. While invaluable for predicting human risk margins—such as in pesticide labeling or drug development where lower LD50 values indicate higher potency—its determination has sparked debate over animal welfare due to the inherent lethality of tests, prompting refinements like fixed-dose procedures or in vitro alternatives, though these often yield less precise empirical data for extrapolating causal toxicity mechanisms. Typically reported in milligrams per kilogram of body weight (mg/kg), LD50 values vary by species, age, sex, and exposure duration, underscoring the need for route-specific testing to reflect real-world causal pathways from absorption to systemic failure.

Core Concepts

Median Lethal Dose (LD50)

The (LD50) denotes the single dose of a toxic substance that causes the death of 50% of a test , typically laboratory animals such as rats or mice, within a specified observation period, often 14 days. This metric quantifies by establishing a statistical on the dose-response curve, where mortality probability reaches 50%, enabling comparisons of substance potency across routes of administration like oral, dermal, or . Lower LD50 values indicate greater , with units conventionally reported as milligrams per kilogram of body weight (mg/kg) for dose-based measures. Determination of LD50 involves administering graded doses to groups of , recording mortality, and applying statistical models to estimate the median. Classical procedures used up to 100 divided into dose cohorts, but contemporary methods, such as those aligned with guidelines, reduce numbers through sequential testing or fixed-dose protocols while maintaining estimability. The LD50 is calculated via techniques including or , , or arithmetical approximations like the Spearman-Kärber method, fitting observed mortalities to a dose-response function. Variability arises from factors including , , , , status, and environmental conditions, necessitating replication for reliability. LD50 data inform regulatory classification of under frameworks like the Globally Harmonized System (GHS), which categorizes substances into hazard levels based on LD50 thresholds to guide labeling, handling, and exposure limits.
GHS CategoryOral LD50 (mg/kg body weight)
1≤ 5
2>5 to ≤ 50
3>50 to ≤ 300
4>300 to ≤ 2000
5>2000 to ≤ 5000
Despite its utility in hazard assessment and setting occupational exposure standards, LD50 exhibits interspecies extrapolation challenges, as animal responses do not uniformly predict outcomes, requiring margins (e.g., factors of 10 to ). It captures only short-term lethal effects, omitting sublethal, , or mechanistic insights, and issues persist due to biological heterogeneity. Ethical critiques highlight animal suffering, prompting shifts toward alternatives and reduced-use protocols since the early .

Lowest Lethal Dose (LDLo)

The lowest lethal dose (LDLo) represents the minimum dosage of a substance, administered via a non-inhalation route, that has been documented to cause in at least one within an experimental or, less commonly, humans. This metric derives directly from observed outcomes in studies rather than probabilistic , marking the threshold where lethality was empirically confirmed at the lowest tested or reported level. Unlike extrapolated values, LDLo relies on discrete case reports, making it particularly applicable in scenarios with sparse data where full dose-response curves cannot be established. Determination of LDLo involves compiling the smallest dose from validated toxicological records that resulted in fatality, typically expressed in milligrams per of body weight (mg/kg). It is not derived through statistical modeling but identified retrospectively from acute exposure experiments or accidental human incidents, emphasizing empirical observation over inference. For instance, regulatory agencies like the Agency for Toxic Substances and Disease Registry (ATSDR) define it explicitly as the lowest reported non-inhalation dose causing death, underscoring its role in highlighting potential hazards without requiring large sample sizes. In comparison to the (LD50), which estimates the dose fatal to 50% of a test via statistical methods like probit analysis, LDLo provides a conservative focused on the extreme lower bound of . This distinction is critical: LD50 assumes a sigmoidal dose-response curve and multiple dose groups for , whereas LDLo captures rare, events and may overestimate risk for broader s due to individual variability or study artifacts. LDLo's simplicity facilitates its use in preliminary hazard assessments, especially for substances with limited testing, but it lacks the of LD50 for population-level ranking. Applications of LDLo include informing material safety data sheets (MSDS) and initial regulatory screenings, where it signals the onset of lethal potential without implying effects. Limitations arise from its dependence on anecdotal or small-scale reports, potentially inflating perceived if the fatal case involved factors like pre-existing conditions or impurities, and it does not account for at equivalent or higher doses in other subjects. Thus, LDLo serves as a supplementary indicator in , best integrated with other metrics for comprehensive risk evaluation rather than standalone interpretation.

Lethal Concentration Measures (LC50 and LCLo)

The LC50, or median lethal concentration, represents the concentration of a substance in air, , or another medium that causes in 50% of a test , typically for studies or organisms for , under controlled conditions over a specified duration such as 4 hours for gases or 96 hours for . This value is derived statistically from dose-response data obtained in tests, where groups of animals or organisms are exposed to graded concentrations, mortality is recorded, and methods like or analysis estimate the median point on the sigmoidal curve. Lower LC50 values indicate higher , with units commonly expressed in milligrams per liter (mg/L) for liquids or parts per million (ppm) for gases, adjusted for time to allow comparability across studies. In contrast, the LCLo, or lowest lethal concentration, denotes the lowest concentration of a substance reported to have caused death in any member of the test population during an exposure period, serving as a conservative threshold for potential lethality rather than a probabilistic median. Unlike the LC50, which requires multiple exposure levels and statistical interpolation, the LCLo is an empirical minimum from observational data, often derived from limited or historical experiments where full dose-response curves were not generated. This measure is particularly useful for highly toxic substances where ethical or practical constraints limit testing at higher concentrations, providing a baseline for hazard identification in regulatory contexts like occupational exposure limits. Both metrics are integral to and protocols standardized by organizations such as the EPA and , where test subjects are exposed via whole-body chambers for air or static/renewal systems for water, with observations for signs of , mortality, and necropsy to confirm causation. Factors influencing values include species sensitivity (e.g., rats versus ), for aerosols, , and exposure duration, necessitating species-specific reporting and confidence intervals for LC50 to account for variability. These measures complement oral or dermal LD50/LDLo values by addressing exposure routes via environmental media, aiding in classifying substances under systems like GHS for acute hazard categories, where LC50 below 500 ppm/4h signals high danger.

Historical Development

Origins in Early Toxicology

The concept of a lethal dose originated from rudimentary observations of poisoning in antiquity, where substances like and were employed for executions or suicides, with empirical knowledge of approximate quantities sufficient to cause death in adults. However, systematic exploration began in the with (1493–1541), who pioneered the dose-dependent nature of toxicity, asserting that "all things are , and nothing is without ; only the dose makes a thing not a ." Paracelsus conducted animal experiments to delineate therapeutic from fatal exposures, testing chemicals such as mercury, , and on dogs and other species to identify thresholds where small amounts elicited healing effects while larger ones induced convulsions, organ failure, or death, thereby establishing between dosage and lethality through direct observation rather than mere correlation. In the , experimental advanced with (1787–1853), who quantified poison effects via controlled animal dosing, reporting for instance that 0.5–1 gram of proved fatal to dogs within hours, manifesting as gastrointestinal hemorrhage and multi-organ collapse. Orfila's Traité des poisons (1814) detailed such dose-response patterns for alkaloids like (lethal at 30–50 mg/kg in rabbits, causing tetanic spasms) and (fatal at 100–200 mg in smaller animals), emphasizing that lethality varied by species, , and individual , thus shifting from anecdotal to empirical determination of minimal fatal quantities. Claude Bernard (1813–1878) further refined these insights through physiological studies, illustrating graded responses to escalating toxin doses; for , he observed paralysis at low levels (0.1–0.2 mg/kg intravenously in dogs) progressing to and at higher thresholds, while experiments revealed saturation levels correlating with coma and fatality around 50–60% . Bernard's work in Introduction à l'étude de la médecine expérimentale (1865) underscored causal mechanisms, such as inhibition or blockade, linking specific doses to lethal outcomes without assuming uniform thresholds across populations. These pre-20th-century investigations, grounded in and data, prioritized verifiable physiological endpoints over probabilistic statistics, revealing early recognition of inter-individual variability in susceptibility.

Standardization and Widespread Adoption

The median lethal dose (LD50) was introduced by British pharmacologist John William Trevan in his 1927 paper "The Error of Determination of Toxicity," published in the Proceedings of the Royal Society B, to address the limitations of earlier toxicity assessments that relied on minimal lethal doses (LDmin). These prior measures were highly variable due to biological differences among test subjects and lacked statistical rigor, rendering inter-laboratory comparisons unreliable for standardizing potent biological preparations like toxins, sera, and early therapeutics. Trevan advocated for the LD50 as a probabilistic endpoint—the dose expected to kill 50% of a uniform test population under controlled conditions—calculated via dose-response curves and error estimation, enabling more reproducible potency evaluations for substances such as digitalis and insulin extracts. Initial adoption centered on biological standardization efforts in the late 1920s and 1930s, particularly in the and , where the LD50 facilitated quality control for , antitoxins, and pharmaceuticals derived from natural sources with inherent variability. For instance, it was applied to standardize insulin potency following the British Pharmacopoeia's guidelines, which required LD50-based assays to ensure consistency across manufacturers. This statistical approach reduced reliance on subjective thresholds, promoting harmonization in pharmacological testing amid growing regulatory demands for post the 1937 Elixir disaster . By the 1940s, amid chemical warfare research and postwar pesticide development, the LD50 achieved broader international uptake in for assessing acute hazards of synthetic compounds, including insecticides like , whose LD50 values informed early environmental risk evaluations. U.S. agencies such as the (FDA), established under the 1938 Federal Food, Drug, and Cosmetic Act, integrated LD50 data into pre-market safety reviews for food additives and drugs, while the (WHO) began referencing it in 1948 for global standards. Advancements like the 1949 Litchfield-Wilcoxon graphical method simplified LD50 computation, accelerating its entrenchment in academic, industrial, and regulatory protocols worldwide. This standardization extended to non-pharmaceutical domains by the , with LD50 tests becoming routine in occupational health assessments for industrial solvents and , as evidenced by their inclusion in the American Industrial Hygiene Association's guidelines. However, adoption was not uniform; some European nations initially favored alternative endpoints due to concerns emerging in the , though the metric's empirical utility in dose-response modeling sustained its dominance until ethical and computational alternatives gained traction decades later.

Measurement and Protocols

In Vivo Testing Procedures

In vivo testing for lethal dose determination, such as the (LD50), primarily utilizes like rats or mice to assess through controlled administration of the test substance and subsequent monitoring for mortality. These procedures follow standardized protocols from organizations like the to ensure reproducibility, with female animals often preferred due to lower variability in sensitivity compared to males. Testing routes include oral gavage, dermal application, or , selected based on anticipated , with oral being most common for systemic LD50 evaluation. Traditional methods involve dosing groups of 5–10 young adult animals (typically 8–12 weeks old, 200–300 g for rats) at 4–5 logarithmically spaced levels designed to bracket 0–100% mortality, followed by a 14-day period during which body weight, clinical , and deaths are recorded daily. Necropsies are performed on deceased and surviving animals to identify gross , with LD50 estimated via statistical methods like analysis on the dose-mortality data. However, these group-based approaches, which can require 30–50 animals per substance, have been largely supplanted by sequential testing to comply with the 3Rs principle (, , refinement) and minimize animal use. The Test Guideline 425 outlines the Up-and-Down Procedure (UDP), a sequential starting with a single animal at an initial dose (often 1750 mg/kg for oral tests, adjustable based on prior data), escalating by a factor of 3.2-fold if the animal survives 48 hours or descending if it dies, continuing until up to 5–15 animals are tested or a stopping criterion (e.g., three consecutive same-direction outcomes) is met. This approach estimates LD50 using maximum likelihood methods, typically requiring fewer animals (maximum 15 per sex) while providing confidence intervals, though it assumes rapid lethality (within days) and may be less precise for substances with delayed effects. Similarly, 423's Acute Toxic Class uses three animals per starting dose class (e.g., 5, 50, 300, 2000 mg/kg), advancing or retreating based on mortality to classify without full LD50 quantification unless partial data allow estimation. All procedures mandate humane endpoints, such as euthanasia for severe distress, and adherence to GLP (Good Laboratory Practice) for data integrity, with environmental controls (e.g., 12-hour light-dark cycle, 22±3°C temperature) to reduce extraneous variability. Inhalation tests (for LC50) adapt similar principles, exposing rodents in whole-body chambers to graded concentrations for 4 hours, monitoring respiratory distress and mortality over 14 days. These methods prioritize empirical dose-response data but face criticism for interspecies extrapolation limitations and ethical concerns, driving ongoing shifts toward in vitro alternatives where validated.

Dose-Response Analysis and Statistical Estimation

Dose-response analysis in quantifies the relationship between administered dose of a substance and the probability of a lethal outcome in a test population, typically using quantal data where outcomes are ( or ). For acute , the response is plotted as the proportion of subjects dying against the logarithm of the dose, yielding a sigmoidal curve that reflects the cumulative distribution of individual tolerances. This curve's steepness indicates variability in sensitivity among subjects, with the (LD50) corresponding to the where 50% mortality occurs. Statistical estimation of the LD50 relies on parametric models fitted to experimental data via maximum likelihood methods. , introduced in and widely adopted in , transforms the response probability using the inverse cumulative (probit), then applies against log-dose to estimate slope and intercept parameters; the LD50 is derived as the log-dose where the predicted probit equals 5 (50% response). models similarly use the for transformation, offering comparable estimates but differing slightly in tail behavior, with software like R's glm or specialized tools computing both alongside 95% confidence intervals via fiducial limits or . These methods account for variance in mortality counts per dose group, enabling hypothesis tests for parallelism across substances or strains. In practice, data from protocols—such as grouped dosing in traditional assays or sequential dosing in the Test No. 425 Up-and-Down Procedure—feed into these estimations to minimize animal use while achieving reliable point estimates and intervals. The Up-and-Down method starts with a pilot dose and adjusts sequentially based on outcomes (up if survival, down if death), culminating in maximum likelihood LD50 calculation that incorporates the entire sequence's likelihood under a or assumption, often yielding estimates with coefficients of variation under 20% using 5-15 animals. Confidence intervals reflect data precision, widening with steeper slopes or fewer observations, and are essential for regulatory classification, though assumptions of log-normality in tolerances can bias results if violated by responses.

Units, Interpretation, and Comparative Assessment

Standard Units and Reporting

The (LD50) is conventionally reported in units of milligrams of substance per of body weight (mg/kg), normalizing to the test subject's mass for comparability across and studies. This unit applies primarily to dose-based measures like oral or dermal LD50, where the administered amount is quantified relative to body weight, enabling statistical estimation from dose-response curves. For highly toxic substances yielding low LD50 values, the unit remains mg/kg, while less toxic ones may use grams per (g/kg) for practicality, though mg/kg predominates in regulatory reporting to maintain precision. Reporting standards, as outlined in guidelines from organizations like the and EPA, mandate specification of the administration route (e.g., oral, dermal, intravenous), test species (typically rats or mice), strain, sex, age, and fasting status, alongside the vehicle used for dosing and observation period—usually 14 days post-exposure to capture delayed mortality. The LD50 value itself is a point estimate derived from or analysis of mortality data, often accompanied by a 95% to quantify uncertainty, with lower and upper bounds reflecting variability in small sample sizes (e.g., 5–10 animals per protocol). For inhalation-based lethal concentration (LC50), units shift to milligrams per liter of air (mg/L) or parts per million () for gases, reported with exposure duration (e.g., 4 hours) and respiratory dynamics considered. These conventions facilitate hazard classification under systems like the Globally Harmonized System (GHS), where LD50 ranges in mg/kg delineate categories (e.g., <5 mg/kg for Category 1 acute toxicity), but reporting emphasizes raw data transparency over aggregated categories to allow independent verification. Variability in units arises from practical constraints, such as solubility limits or ethical reductions in animal use via up-and-down procedures, yet core reporting prioritizes body-weight normalization to isolate intrinsic potency from extrinsic factors like absorption efficiency.

Toxicity Classification Systems

The Globally Harmonized System of Classification and Labelling of Chemicals (GHS), administered by the United Nations Economic Commission for Europe (UNECE), standardizes classification worldwide using LD50 values to assign substances to one of five categories, with Category 1 indicating the highest . This system relies on approximate LD50 or estimates (ATE) derived from or validated alternatives, applying route-specific criteria for oral, dermal, or exposure. Categories 1–4 trigger mandatory labeling with pictograms (e.g., for ), while Category 5 covers less severe hazards expected to produce LD50 values up to 5,000 mg/kg, often without pictograms but with precautionary statements. GHS oral acute toxicity criteria are defined as follows:
CategoryLD50 (mg/kg body weight)
1≤ 5
2> 5 – ≤ 50
3> 50 – ≤ 300
4> 300 – ≤ 2,000
5> 2,000 – ≤ 5,000
Dermal and thresholds differ slightly, with LC50 measured in mg/L/4h for vapors or gases, ensuring harmonized communication across borders while accounting for exposure route variability. In the United States, the Environmental Protection Agency (EPA) employs a distinct four-category system for under 40 CFR 156.62, prioritizing LD50/LC50 data to determine signal words and labeling requirements, with Category I denoting the greatest hazard. This framework, established to protect handlers and applicators, assigns categories based on the most toxic route of exposure and influences precautionary statements independently of GHS. For oral exposure, Category I includes substances with LD50 ≤ 50 mg/kg, escalating to Category IV for > 5,000 mg/kg, often correlating with signal words "DANGER—POISON" for I, "WARNING" for II–III, and "CAUTION" for IV. EPA oral acute toxicity categories are outlined below:
CategoryOral LD50 (mg/kg)Signal Word
I≤ 50DANGER—
II> 50 – ≤ 500
III> 500 – ≤ 5,000
IV> 5,000CAUTION
These systems, while overlapping (e.g., GHS Category 1 aligns roughly with EPA I for high ), differ in and application—GHS emphasizes global trade and mixtures via ATE calculations, whereas EPA focuses on end-use products—necessitating dual compliance in jurisdictions like the U.S. Historical scales, such as the Hodge-Sterner classification (rating from 6 for super toxic, LD50 < 50 μg/kg, to 1 for relatively non-toxic, LD50 > 15 g/kg), inform modern protocols but lack regulatory mandate today. Classifications assume single-exposure scenarios and do not capture effects, underscoring their role as acute indicators rather than comprehensive assessments.

Practical Applications

Regulatory Hazard Classification

Regulatory agencies worldwide employ lethal dose data, primarily the LD50 value, to classify substances for under the Globally Harmonized System of and Labelling of Chemicals (GHS), which has been adopted or aligned with by bodies such as the (OSHA) in the United States and the , Labelling and Packaging (CLP) Regulation in the . GHS defines five categories based on the median lethal dose required to kill 50% of test subjects via oral, dermal, or routes, with lower LD50 values indicating higher levels that trigger specific pictograms, signal words like "Danger," and precautionary statements on labels and safety data sheets. For mixtures, acute toxicity estimates (ATE) derived from component LD50 data are used when direct testing is unavailable. The classification criteria for oral acute toxicity under GHS, expressed in LD50 mg/kg body weight, are as follows:
CategoryLD50 (mg/kg)Hazard Statement Example
1≤ 5Fatal if swallowed
2> 5 – ≤ 50Fatal if swallowed
3> 50 – ≤ 300Toxic if swallowed
4> 300 – ≤ Harmful if swallowed
5> – ≤ 5000May be harmful if swallowed
Dermal and inhalation classifications follow analogous thresholds adjusted for LC50 in gases, vapors, dusts, and mists, with OSHA's Hazard Communication mandating these for workplace chemical inventories since its 2012 alignment with GHS Revision 3. In the EU, the , effective since 2015 for full implementation, mirrors these GHS criteria, requiring notification to the for substances in categories 1-3. The U.S. Agency (EPA) integrates similar LD50-based assessments for pesticide labeling and hazardous waste identification, where acute oral toxicity is flagged if LD50 is below 50 mg/kg for certain listings or 2,500 mg/kg for characteristic toxicity under criteria. These classifications inform regulatory controls, such as restricted handling, transportation requirements under UN Model Regulations, and limits, prioritizing empirical LD50 data from validated while allowing bridging principles for data gaps. Despite harmonization, national variations persist; for instance, GHS Category 5 is optional in some jurisdictions like the U.S. OSHA standard, reflecting judgments on practical enforceability and risk communication efficacy.

Safety Assessment in Pharmaceuticals and Chemicals

In pharmaceutical development, testing, including determination of the LD50 in species such as rats or mice, evaluates the potential for immediate life-threatening effects from overdose or accidental exposure, informing decisions on compound progression and initial human dosing. This metric helps calculate the as the ratio of LD50 to the median effective dose (ED50), providing a quantitative margin of that guides dose escalation in phase I clinical trials. For instance, compounds with low LD50 values (e.g., below 50 mg/kg orally in rats) may be deprioritized due to narrow safety windows, as seen in early screening of investigational drugs. Regulatory frameworks, such as those from the International Council for Harmonisation (ICH), integrate LD50 data into preclinical safety packages, though emphasis has shifted toward limit tests or no-observed-adverse-effect levels (NOAELs) to minimize animal use while still requiring evidence of acute lethality thresholds for new chemical entities. The U.S. (FDA) mandates acute oral toxicity studies under 21 CFR 58 for nonclinical assessments, where LD50 estimates support hazard identification before advancing to repeated-dose . In chemical safety assessment, LD50 values classify substances for handling, transport, and environmental release under systems like the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). For oral exposure, GHS Category 1 denotes extreme (LD50 ≤ 5 mg/kg), Category 2 (5 < LD50 ≤ 50 mg/kg) high toxicity, and so forth up to Category 5 (>2000 mg/kg), triggering signal words like "Danger" and skull-and-crossbones pictograms for the most hazardous. Agencies such as the U.S. Environmental Protection Agency (EPA) rely on LD50 data from standardized protocols like OPPTS 870.1100 for pesticide registration and Toxic Substances Control Act (TSCA) inventories, using point estimates and confidence intervals to derive reference doses or acceptable exposure levels with uncertainty factors (typically 10-fold for interspecies extrapolation). The Organisation for Economic Co-operation and Development (OECD) Test No. 425 employs an up-and-down procedure to estimate LD50 for industrial chemicals with fewer animals (e.g., 5-15 per test), supporting REACH registrations in the European Union by characterizing acute hazards and informing derived no-effect levels (DNELs).
GHS Acute Oral Toxicity CategoryLD50 Range (mg/kg body weight)Hazard Statement Example
1≤ 5Fatal if swallowed
2>5 to ≤50Fatal if swallowed
3>50 to ≤300Toxic if swallowed
4>300 to ≤2000
5>2000 to ≤5000May be harmful if swallowed
These assessments extend to occupational and consumer product safety, where low LD50 chemicals (e.g., certain pesticides with LD50 <100 mg/kg) require personal protective equipment and restricted access, as codified in EPA's worker protection standards updated in 2015. In both pharmaceuticals and chemicals, LD50 data underpin probabilistic risk models, such as those incorporating exposure distributions to estimate population-level margins exceeding 100-fold for non-cancer endpoints.

Scientific Limitations

Variability Factors and Reliability Issues

The determination of lethal doses, such as the median lethal dose (LD50), is subject to significant variability arising from biological differences within and across species. Intraspecies factors include genetic strain, age, sex, body weight, health status, and , which can alter responses; for instance, younger often exhibit heightened due to immature pathways, while sex-specific differences in may shift LD50 values by factors of 1.5 to 2 in mice exposed to certain toxins like yessotoxin. Interspecies variability is even more pronounced, driven by differences in absorption, distribution, , and excretion () processes; species display greater dispersion in lethal levels compared to mammals, with allometric scaling based on body weight often failing to account for phylogenetic divergences, leading to extrapolation errors of up to an between and humans. Experimental conditions further exacerbate variability, including (e.g., oral versus intraperitoneal, which can differ LD50 by 10-fold or more), used for dosing, environmental stressors like temperature or housing density, and even microbial gut flora influencing . Laboratory-specific protocols, such as duration or sample size (typically 10-20 per group), introduce additional noise, with intraspecies coefficients of variation in rat oral LD50 often ranging from 20-50% across studies due to these uncontrolled variables. Peer-reviewed compilations of data highlight that such factors confound , as evidenced by surveys of LD50 literature showing inconsistent classifications under schemes like GHS when mean values are recalculated. Reliability issues stem from the statistical nature of LD50 estimation, which relies on dose-response curves fitted via or logistic models to interpolate the dose killing 50% of a test , yet small cohorts yield wide confidence intervals (sometimes exceeding 50% of the point estimate) and high sensitivity to outliers. Inter-laboratory comparisons reveal poor concordance, with the same chemical's LD50 varying by factors of 2-5 due to strain heterogeneity or procedural differences, undermining the metric's precision for regulatory thresholds. Moreover, historical reliance on acute tests overlooks chronic or subacute mechanisms, and their predictive power for lethality is limited, as models fail to forecast in approximately 50% of pharmaceutical cases, attributable to unmodeled pharmacokinetic disparities rather than mere scaling errors. These limitations necessitate uncertainty factors (e.g., 10-fold for interspecies differences) in , though even these may not fully capture causal variabilities in real-world exposures.

Challenges in Extrapolating to Human Risk

Extrapolating lethal dose data, such as LD50 values, from animal models to humans is fraught with uncertainties arising from interspecies physiological, metabolic, and pharmacokinetic differences that alter toxicity responses. Animals and humans exhibit variations in absorption, distribution, metabolism, and excretion (ADME) processes; for instance, rodents often metabolize compounds more rapidly than humans, leading to underestimation or overestimation of human risk depending on whether detoxification or bioactivation occurs. These differences can result in metabolites forming in one species but not another, producing species-specific toxicities irrelevant to humans. Dose scaling methods, such as allometric principles based on body weight or surface area, frequently fail to accurately predict equivalents from LD50 . Linear body weight extrapolations ignore nonlinear pharmacokinetic scaling, yielding poor concordance; empirical analyses of LD50 across show minimal alignment with body weight^{3/4} or other allometric exponents. For acute toxicities, body weight scaling (BW^{1.0}) performs marginally better for severe exposures but still requires -specific adjustments to avoid inaccuracies. Route-of-administration discrepancies further complicate matters, as oral LD50 in may not reflect dermal or exposures, amplifying extrapolation errors. Empirical comparisons reveal substantial predictive limitations, with toxicity correlating weakly to outcomes; a review of pharmaceuticals found models identifying toxicities with only 65% positive predictive value and 50% negative predictive value. Historical analyses, such as Zbinden and Flury-Roversi's comparison of LD50s to poisoning cases, documented frequent discrepancies, including cases where overestimated for certain pesticides or underestimated it for others. These failures underscore risks of false negatives (missing hazards) or false positives (overly conservative restrictions), prompting regulatory use of uncertainty factors—typically 10-fold for interspecies differences—to buffer extrapolations, though such margins remain empirically derived rather than mechanistically precise. Human population variability, including , age, health status, and comorbidities, adds layers of uncertainty absent in inbred strains, further eroding reliability. Without direct human lethality data—ethically unobtainable for most substances—reliance on LD50 perpetuates these challenges, highlighting the need for integrated approaches like physiologically based pharmacokinetic modeling to refine predictions.

Ethical and Regulatory Debates

Animal Testing Welfare Concerns

for lethal dose determination, exemplified by the traditional LD50 assay, elicits significant welfare concerns due to the intentional infliction of severe distress and mortality on sentient subjects. In these protocols, groups of —typically rats or mice—are administered graded doses of the test substance, often through invasive methods like oral gavage, which involves via a tube inserted into the . Animals are monitored for up to 14 days, with serving as the endpoint to calculate the dose lethal to 50% of the population; this process commonly requires 60 to 100 animals per test to achieve statistical precision. Test subjects endure acute toxic manifestations prior to death, including tremors, convulsions, , , respiratory distress, and other signs of profound physiological disruption, reflecting unalleviated pain and . Such procedures fall under USDA Category E classifications, denoting experiments involving distress without , analgesics, or intervention, as pain relief could confound observations by masking symptoms. This regulatory tolerance for unrelieved agony underscores tensions between scientific imperatives and animal , with critics noting that symptoms like muscle spasms and lacrimation indicate experiential akin to that in humans. The cumulative scale amplifies these issues, with millions of subjected to endpoints annually in assessments worldwide, prompting ethical over the justification of mass-scale for whose interspecies remains imperfect. While refinements have curtailed animal numbers in some variants (e.g., to 10-40 via sequential dosing), the persistence of fatal outcomes and distress in core methodologies fuels ongoing debates about balancing human safety gains against the inherent of inducing deliberate .

Implementation of the 3Rs Principle

The 3Rs principle—, , and refinement—has driven modifications to protocols for determining lethal doses in testing, shifting from the classical (LD50) , which typically required 30 to 100 animals per test, to streamlined methods endorsed by regulatory bodies like the (OECD). These alternatives prioritize hazard classification under systems such as the Globally Harmonized System (GHS) over precise LD50 estimation, thereby aligning with ethical standards while supporting . Reduction in animal numbers is achieved through OECD Test Guidelines 420, 423, and 425, which employ sequential or adaptive dosing strategies. OECD TG 423, the Acute Toxic Class method, uses fixed doses (5, 50, 300, or 2000 mg/kg) tested in groups of three animals (typically rats) per step, with a maximum of 9 to 12 animals needed for GHS categorization, representing a 40-70% decrease compared to traditional LD50 protocols. Similarly, TG 420 (Fixed Dose Procedure) limits initial testing to 10 animals (five per sex) at predefined non-lethal doses, expanding only if necessary up to 40, while TG 425 (Up-and-Down Procedure) adjusts doses based on individual outcomes, often requiring just 2 to 15 animals. Adoption of these guidelines has substantially lowered overall animal use; for example, in , over 85% of tests by 2003 utilized the Acute Toxic Class method. Refinement minimizes suffering by replacing death as the primary with humane criteria, such as observable clinical signs of severe (e.g., convulsions, , or ), allowing early as outlined in the OECD Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints (2000). This approach, integrated into TG 420, 423, and 425, reduces the duration and intensity of distress, though moribund states may still occur in up to 50% of cases in some tests. Regulatory frameworks, including those from the U.S. Environmental Protection Agency and , mandate consideration of these endpoints to comply with laws. Replacement remains partial, with in vitro assays like the 3T3 Neutral Red Uptake test validated for preliminary screening but insufficient for systemic lethal dose classification without data corroboration. Computational models and read-across from structural analogs are increasingly used for waiving tests under regulations like EU REACH, yet full regulatory replacement for vertebrates persists as a challenge due to validation gaps in predicting whole-organism effects. Despite these advances, implementation has not eliminated use entirely, as alternatives must demonstrate equivalent predictivity for .

Modern Alternatives and Advances

In Vitro and Computational Prediction Methods

In vitro methods for predicting lethal doses primarily rely on assays using immortalized cell lines, such as fibroblasts or hepatocytes, to measure endpoints like cell viability, membrane permeability, or metabolic activity as proxies for systemic . Basal models, which assess non-specific mechanisms like disruption of energy production or lysosomal function, often correlate inversely with LD50 values, where lower in vitro concentrations (half-maximal inhibitory concentrations) indicate higher toxicity potential. For example, neutral red uptake and MTT reduction assays have been validated to predict oral LD50 within a of 5 for many chemicals, supporting their use in hazard classification under frameworks like the Globally Harmonized System (GHS). A comparative study of 48 compounds found that in vitro basal data accurately forecasted in vivo LD50 for at least 75% of cases, though predictions were less reliable for compounds acting via specific organ toxicities rather than general cellular damage. High-throughput screening platforms, such as the Tox21 program, have advanced prediction by integrating assays for over 10,000 chemicals across multiple and stress response pathways, enabling machine-readable data for acute systemic toxicity classification. A 2024 analysis demonstrated that Tox21-derived features, when combined with chemical structures, outperformed structure-only models in distinguishing toxic from non-toxic agents, with accuracy exceeding 80% for binary outcomes akin to LD50 categories. These methods reduce animal use by providing starting doses for limited tests or direct read-across to human-relevant endpoints, though they underpredict potency for chemicals requiring metabolic activation, as standard cell lines lack full metabolism capabilities. Computational prediction methods, particularly quantitative structure-activity relationship (QSAR) models, estimate LD50 by correlating molecular descriptors—such as topological indices, electronic properties, and hydrophobicity—with empirical toxicity data from large databases. Regression-based QSARs for rat acute oral LD50 have been developed using datasets of thousands of compounds, achieving correlation coefficients (R²) of 0.7–0.8 and mean absolute errors within one order of magnitude for external validations. Tools like the U.S. EPA's Toxicity Estimation Software Tool (TEST) employ consensus approaches, averaging predictions from multiple QSAR algorithms (e.g., hierarchical clustering and FDA methods), to classify toxicity categories with reported accuracies of 70–85% against OECD test guidelines. Machine learning enhancements, including random forests and neural networks trained on structural fingerprints, have improved QSAR applicability to diverse chemical spaces, such as pesticides or nerve agents, where models predict LD50 with errors of 0.3–0.5 units. For instance, a 2019 study on over 7,000 LD50 values yielded models distinguishing GHS categories (e.g., LD50 < 300 mg/kg as Category 1) with balanced accuracies above 75%, outperforming traditional linear regressions for imbalanced datasets. Hybrid in silico-in vitro workflows, such as those integrating Tox21 data into QSAR inputs, further refine predictions by accounting for and mode-of-action, as validated in regulatory tools like and CATMoS with consensus LD50 estimates correlating at ~80% to experimental values. These approaches are increasingly accepted for waiving full animal LD50 tests under REACH and EPA guidelines when applicability domains are defined and uncertainties quantified.

Machine Learning and AI-Driven Models

models for lethal dose prediction primarily employ for quantitative LD50 estimation or for toxicity categories, utilizing chemical descriptors, molecular fingerprints, and graph neural networks trained on public datasets such as Li et al., SuperToxic, and ECOTOX. These approaches integrate techniques like random forests, support vector machines, and deep neural networks to infer from structural features, offering computational speed and scalability as alternatives to testing. For instance, the deepAOT model, a multi-graph convolutional neural network developed in 2017, achieves a of 0.864 and error of 0.268 for LD50 on approximately 12,200 compounds, while its multiclassification variant reaches 96% accuracy in assigning EPA acute oral categories. Deep learning advancements, including hybrid neural networks, further refine dose-response predictions by capturing non-linear relationships in data. The HNN-Tox model, introduced in 2022, combines convolutional and recurrent layers to forecast across dose ranges, demonstrating improved generalization over traditional quantitative structure-activity relationship methods on benchmark datasets. Similarly, etoxPred (2019) applies extra trees to the SuperToxic database of over 12,000 compounds, yielding an area under the curve of 0.80 and accuracy of 0.854 for binary classification aligned with LD50 thresholds. Tools like ProTox-3.0 integrate 61 models with fragment propensity and similarity scoring to predict rodent LD50 values and classify them into Globally Harmonized System classes, facilitating rapid screening without animal experimentation and adhering to the 3Rs principle of reduction, refinement, and replacement. Recent integrations, such as graph neural networks in ADMETlab 3.0 (2024), extend these capabilities to multi-endpoint forecasting with area under the curves approaching 0.94 for related acute endpoints, supporting early-stage filtering in to minimize animal use. However, model performance hinges on dataset quality and size, with potential or underrepresentation of novel chemicals limiting real-world reliability; external validation remains essential, as internal cross-validation metrics like those in deepAOT may not fully capture challenges. These AI-driven methods align with regulatory pushes, such as FDA's AI4TOX initiatives, for alternatives, though they complement rather than fully supplant empirical validation due to causal complexities in dose .

References

  1. [1]
    [PDF] Chapter IV. Guidelines for Toxicity Tests - FDA
    The median lethal dose (or LD50) is defined as the dose of a test substance that is lethal for 50% of the animals in a dose group.
  2. [2]
    Determination of Median Lethal Dose of Combination of Endosulfan ...
    The commonly used term to describe acute toxicity is LD50, where LD means lethal dose deadly amount, and the subscript 50 means that the dose is acutely lethal ...
  3. [3]
    [PDF] Understanding Pesticide Toxicity
    This is the amount of an ingested substance (single dose) that causes the death of 50% of a group of test subjects. The LD50 is expressed in milligrams of.
  4. [4]
    What is a LD₅₀ and LC₅₀? - CCOHS
    Who invented the idea of an LD50? ... In 1927, J.W. Trevan attempted to find a way to estimate the relative poisoning potency of drugs and medicines used at that ...Missing: history | Show results with:history
  5. [5]
    A Review of the LD50 and Its Current Role in Hazard Communication
    Dec 21, 2020 · ... toxicity data alone. (13−15) Further, there are acute inhalation ... Important to Clinical and Forensic Toxicology. Chemical Research ...
  6. [6]
    The role of the LD50 determination in drug safety evaluation - PubMed
    Acute toxicology studies in animals are essential to drug development. Often such experiments seek to establish precisely the median lethal dose (LD50) in ...
  7. [7]
    [PDF] Acute Toxicity Tests LD50 (LC50) Determinations and Alternatives
    To describe the purpose of acute toxicity tests and the utility of. LD50 (LC50) values, a) in regulatory notifications, b) as a contribution to the scientific ...
  8. [8]
    7.7.2 Evaluating Toxicity Data | Environment, Health and Safety
    The LD50 describes the amount of chemical ingested or absorbed by the skin in test animals that causes death in 50% of test animals used during a toxicity test ...Missing: definition | Show results with:definition
  9. [9]
    Advances in acute toxicity testing: strengths, weaknesses and ... - NIH
    History and timeline of acute toxicity testing. 1920s: The conventional or Classical LD50 test. This is the first acute toxicity test that was developed in the ...
  10. [10]
    GHS Classification Criteria for Acute Toxicity - ChemSafetyPro.COM
    Mar 6, 2018 · LD50 and LC50 values are needed for GHS classification. Acute toxicity category 1 represents the most severe toxicity. GHS classification acute ...
  11. [11]
    [PDF] 10. GLOSSARY - Agency for Toxic Substances and Disease Registry
    Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or ...
  12. [12]
    The MSDS HyperGlossary: LDLo, Lowest Lethal Dose
    An LDLo or Lowest Lethal Dose value is the lowest amount of a solid or liquid material reported to have caused the death of animals or humans.
  13. [13]
    [PDF] 9. GLOSSARY - ATSDR
    Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated to cause death in 50% of a defined experimental animal population. Lethal Time(50) ( ...Missing: toxicology | Show results with:toxicology
  14. [14]
    [PDF] Appendix A. Glossary of Useful Terms - EPA
    LC50 (Lethal Concentration 50) – Median lethal concentration is the concentration of a pollutant at which 50% of the test organisms die; a common measure of ...
  15. [15]
    [PDF] Using Toxicity Tests in Ecological Risk Assessment - EPA
    This dilution (also referred to as a concentration), called the LC50, is the median lethal concentration. When an acute toxicity test reports an LC50, the.<|separator|>
  16. [16]
    7.7.2 Evaluating Toxicity Data - Cornell EHS
    As a general rule of thumb, the lower the LD50 or LC50 number, the more toxic the chemical. Note there are other factors (concentration of the chemical, ...
  17. [17]
    [PDF] Safe Handling of Extremely and Highly Toxic Materials
    LC50 is defined as the concentration in air at which 50 percent of the test animals (rats or mice) died, usually within 1 hour. A substance is considered ...
  18. [18]
    The MSDS HyperGlossary: LC-Lo, Lowest Lethal Concentration
    Oct 18, 2025 · An LCLo value is the lowest concentration of a material in air reported to have caused the death of animals or humans.
  19. [19]
    [PDF] Exposure to a chemical for a duration of 14 days or less, as specified ...
    Lethal Concentration (LO) (LCLO) - The lowest concentration of a chemical in air which has been reported to have caused death in humans or animals. Lethal ...
  20. [20]
    [PDF] Temporary Emergency Exposure Limits for Chemicals
    All toxic concentration data (LC50, LCLO, TCLO) are reduced to a 15-minute exposure time. If the exposure time is not given, 15 minutes is assumed for ...
  21. [21]
    [PDF] EPA Health Effects Test Guidelines: Acute Inhalation Toxicity
    The LC50 value should be considered in conjunction with the observed toxic effects and the necropsy findings. The. LC50 value is a relatively coarse measurement ...
  22. [22]
    Determination of Median Lethal Concentration (LC50) for ...
    Dec 8, 2021 · Endosulfan starts to exert toxic effects on aquatic organisms even at concentrations as low as 0.005 mg/L and hepatotoxic actions can occur ...
  23. [23]
    Extremely and Highly Toxic Chemicals
    LD50 is defined as the dose at which 50 percent of the exposed test animals (generally, rats or mice) died, usually within 1-2 hours after being dosed by ...Missing: toxicology | Show results with:toxicology
  24. [24]
    The dose response principle from philosophy to modern toxicology
    The concept of dose response traces back to 8th century BC, with Hesiod's Harmonia. Mithridates VI Eupator was the first to approach the notion of dose ...
  25. [25]
    Paracelsus Revisited: The Dose Concept in a Complex World - PMC
    At the time that Paracelsus coined his famous dictum, “What is there that is not poison? All things are poison and nothing is without poison.Missing: lethal | Show results with:lethal
  26. [26]
    Toxicology: Then and now - ScienceDirect.com
    Although the history of poisons dates to the earliest times, the study and the science of toxicology can be traced to Paracelsus (1493–1541) and Orfila (1757– ...
  27. [27]
    Poisons and the development of Toxicology in the 19th century
    Jun 26, 2024 · With this, he provided the first description of the dose-response relationship which is at the heart of modern toxicology. As he writes in ...
  28. [28]
    Toxicology rewrites its history and rethinks its future: Giving equal ...
    Sep 19, 2011 · This paper assesses how medicine adopted the threshold dose–response to evaluate health effects of drugs and chemicals throughout the 20th ...
  29. [29]
    The error of determination of toxicity - Journals
    Trevan John William. 1927The error of determination of toxicityProc. R. Soc. Lond. B.101483–514http://doi.org/10.1098/rspb.1927.0030. Section. Abstract ...
  30. [30]
    Background and Definitions - NCBI - NIH
    The use of animals in toxicity studies began in the 1920s to determine the 50% lethal dose (LD50) of a chemical. Rabbit models for eye and skin irritation were ...
  31. [31]
    Alternative Methods for the Median Lethal Dose (LD 50 ) Test
    The LD 50 estimate is calculated using the maximum likelihood method unless the response pattern falls into an exceptional case. All deaths, whether immediate ...
  32. [32]
    Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure | OECD
    It is easiest to apply to materials that produce death within couple of days. This Test Guideline is intended for use with rodents (rat female preferably).
  33. [33]
    [PDF] OECD Test Guideline 425 - National Toxicology Program
    As with any limit test protocol, the probability of correctly classifying a compound will decrease as the actual LD50 more nearly resembles the limit dose.
  34. [34]
    Acute Oral Toxicity Up-And-Down-Procedure | US EPA
    Jan 30, 2025 · It uses sequential dosing, together with sophisticated computer-assisted computational methods during the execution and calculation phases of ...Missing: LDLo | Show results with:LDLo
  35. [35]
    [PDF] Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure (EN)
    Jun 30, 2022 · The test procedure described in this Guideline is of value in minimizing the number of animals required to estimate the acute oral toxicity of ...
  36. [36]
    [PDF] User Documentation for the AOT425 StatPgm Program - EPA
    May 16, 2001 · 425, Acute Oral Toxicity: Up-and-Down Procedure. For convenience purposes, we will refer to that document as OECD TG 425 Procedure. The ...<|separator|>
  37. [37]
    [PDF] Test No. 423: Acute Oral toxicity - Acute Toxic Class Method (EN)
    Dec 17, 2001 · The method allows for the determination of an LD50 value only when at least two doses result in mortality higher than 0% and lower than 100%.
  38. [38]
    [PDF] OECD Test Guideline 425 - Acute Oral Toxicity
    In 1985, Bruce proposed to use an up-and-down procedure (UDP) for the determination of acute toxicity of chemicals (3). There exist several ...
  39. [39]
    Acute Toxicity - The Joint Research Centre: EU Science Hub
    Acute systemic toxicity testing involves an assessment of the general toxic effects of a single dose or multiple doses of a chemical or product, within 24 ...Regulatory Context · Method Deletion · Eurl Ecvam Validated Test...
  40. [40]
    Improved up-and-down procedure for acute toxicity measurement ...
    Jan 4, 2022 · Median lethal dose (LD50) was first proposed by J. W. Trevan in 1976 [1]. It is used to study acute toxicity and classify toxic substance [2].
  41. [41]
    Dose-Response Relationship - an overview | ScienceDirect Topics
    Based on the central role that the dose-response relationship has in the discipline of toxicology, it is not surprising that their history is inseparable.
  42. [42]
    The median lethal dose and its estimation - PubMed
    The present paper draws attention to some statistical aspects of LD50 estimation that a … ... LD50 in an animal species as an adequate guide to toxicity in man.
  43. [43]
    [PDF] Probit Analysis - NCSS
    Probit and logit analysis may be used for comparative LD50 studies for testing the efficacy of drugs designed to prevent lethality. This program module presents ...
  44. [44]
    Probit Analysis (Dose Response Curves, ED50 etc.) - StatsDirect
    Probit analysis fits probit and logit sigmoid dose/stimulus response curves and calculates confidence intervals for dose-response quantiles like ED50.
  45. [45]
    Comparing lethal dose ratios using probit regression with arbitrary ...
    Oct 5, 2018 · Toxicological evidence suggested that the slope of a dose–response regression line reflected host enzyme activity [19]. Thus, non-parallel lines ...
  46. [46]
    [PDF] OECD Guidance Document Number 24: Acute Oral Toxicity Testing
    Jul 23, 2001 · While there exist several variations of the up-and-down experimental design, Guideline 425 is a modification of the procedure of Bruce as ...
  47. [47]
    [PDF] Toxicology Guidance:Performance of the Up-and-Down Procedure
    The UDP guideline uses the maximum likelihood estimation method for calculation of the LD50 and profile likelihood (PL) methods for estimation of most ...Missing: LDLo | Show results with:LDLo
  48. [48]
    Ag 101, Lethal Dosage (LD50) Values - EPA - P2 InfoHouse
    Jun 13, 2018 · An LD50 is a standard measurement of acute toxicity that is stated in milligrams (mg) of pesticide per kilogram (kg) of body weight.Missing: units | Show results with:units
  49. [49]
    [PDF] Test No. 402: Acute Dermal Toxicity (EN) - OECD
    Oct 9, 2017 · The LD50 value is expressed in terms of weight of test chemical per unit weight of test animal (mg/kg bw).
  50. [50]
    [PDF] Variability of LD50 Values from Rat Oral Acute Toxicity Studies - EPA
    Acute oral toxicity testing is commonly used for hazard classification and labeling of potential systemic toxicants. These classifications are based on LD50 ...
  51. [51]
  52. [52]
    [PDF] Chemical Hazard Classification and Labeling: Comparison of OPP ...
    Jul 7, 2004 · GHS Category 5 covers chemicals with toxicities expected to fall in the range of oral and dermal LD50 of 2000 mg/kg -5000 mg/kg, or equivalent ...
  53. [53]
    Overview of the GHS Classification Scheme in Hazard ... - NCBI - NIH
    Chemicals can be classified into five hazard categories based on animal LD 50 (oral, dermal) or LC 50 (inhalation) values.
  54. [54]
    40 CFR 156.62 -- Toxicity Category. - eCFR
    This section establishes four Toxicity Categories for acute hazards of pesticide products, Category I being the highest toxicity category.Missing: LD50 | Show results with:LD50
  55. [55]
    [PDF] Chapter 7: Precautionary Statements | Label Review Manual - EPA
    With the exception of dermal sensitization, each acute study is assigned to a toxicity category based on the study results (See Table 1 below). The results of ...
  56. [56]
    [PDF] GLOBALLY HARMONIZED SYSTEM OF CLASSIFICATION AND ...
    The Globally Harmonized System of Classification and Labelling of Chemicals (GHS) is the culmination of more than a decade of work.
  57. [57]
  58. [58]
    [PDF] Regulation (EU) 2024/2865 of the European Parliament ... - EUR-Lex
    Oct 23, 2024 · Acute toxicity values are expressed as approximate LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates. It is ...
  59. [59]
    [PDF] Hazard Classification Guidance for Manufacturers, Importers ... - OSHA
    known acute toxicity, which fall into any of the acute toxicity categories, or have an oral LD50 > 2000 ≤5000 mg/kg body weight. - Component 3 is excluded ...
  60. [60]
    [PDF] Chemical Hazard Classification and Labeling: Comparison of OPP ...
    Jul 7, 2004 · GHS Category 5 covers chemicals with toxicities expected to fall in the range of oral and dermal LD50 of 2000 mg/kg -5000 mg/kg, or equivalent ...
  61. [61]
    Defining Hazardous Waste | Department of Toxic Substances Control
    As stated in 22 CCR section 66261.24(a)(3), a waste is identified as being toxic if it has an acute oral LD50 less than 2,500 mg/kg. A calculated oral LD50 may ...Missing: lethal | Show results with:lethal
  62. [62]
    The value of acute toxicity testing of pharmaceuticals for estimation ...
    We propose that the acute toxicity based on rat LD 50 dose is not used as a basis for classification of pharmaceuticals, and that the METD is applied as basis ...
  63. [63]
    [PDF] Health Effects Test Guidelines OPPTS 870.1100 Acute Oral Toxicity
    LD50 (median lethal dose), oral, is a statistically derived single dose of a substance that can be expected to cause death in 50 per cent of ani mals when ...
  64. [64]
    [PDF] OECD Guidelines for Testing of Chemicals - EPA
    Dec 17, 2001 · In addition to the estimation of LD50 and confidence intervals, the test allows the observation of signs of toxicity.
  65. [65]
    Principles of dose-setting in toxicology studies: the importance ... - NIH
    This review explains the rationale that compels regulatory toxicology to embrace the advancements made possible by kinetics.
  66. [66]
    Lethal Dose 50% (LD50): AP® Environmental Science Review
    May 7, 2025 · In toxicology, this measurement provides a standard way to compare the toxicity of different substances. The value is typically expressed in ...<|control11|><|separator|>
  67. [67]
    Effect of mouse strain and gender on LD(50) of yessotoxin - PubMed
    Sep 15, 2008 · The aim of the present study was to determine whether the intraperitoneal LD(50) for yessotoxin (YTX) in mice varies with strain or gender.Missing: intraspecies variability age
  68. [68]
    Sensitivity of species to chemicals: Dose–response characteristics ...
    Nov 1, 2013 · Variability of lethal levels (σ) for water exposed cold-blooded species is larger than for orally dosed warm-blooded species reflecting ...
  69. [69]
    Scaling toxicity data across species
    As a result, larger animals are indeed more susceptible to toxicity on a mg kg−1 body weight basis, but this is not because of unique differences in the species ...
  70. [70]
    Prediction of Human Lethal Doses and Concentrations of MEIC ...
    Feb 24, 2021 · Many factors can affect rodent toxicity values, such as species, genetic variability, age, sex, weight, health, diet, administration route, ...
  71. [71]
    Evaluation of Variability Across Rat Acute Oral Systemic Toxicity ...
    Rat acute oral LD 50 data from multiple databases were compiled, curated, and analyzed to characterize variability and reproducibility of results.Missing: intraspecies | Show results with:intraspecies
  72. [72]
    Acute oral toxicity: variability, reliability, relevance and interspecies ...
    Acute oral toxicity: variability, reliability, relevance and interspecies comparison of rodent LD50 data from literature surveyed for the ACuteTox project.
  73. [73]
    Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
    Nov 25, 2019 · Animal models are poor predictors of human drug safety, with high costs, delays, and potential for false safety identification, and ...
  74. [74]
    [PDF] METHODS FOR IDENTIFYING A DEFAULT CROSS-SPECIES ... - EPA
    Detailed modeling of interspecies differences in toxicity from dermal exposures to ... Cross-species and cross-route comparisons of acute lethal doses ...<|separator|>
  75. [75]
    Toxic effects of chemicals: difficulties in extrapolating data ... - PubMed
    This review attempts an analysis of the major components which make it extremely difficult to extrapolate toxicological data obtained with chemicals from ...
  76. [76]
    Extrapolation of animal toxicity to humans: Interspecies comparisons ...
    Different methods for converting the dose-related toxicity of drugs from animals to humans are reviewed. Each method is analyzed with respect to its utility ...
  77. [77]
    Extrapolating Animal Safety and Efficacy Data to Humans
    Oct 2, 2016 · 1. Excessive dosage · 2. Creation of metabolites in animals (but not in humans) that lead to toxicity · 3. Environmental factors favor the lesion, ...Missing: challenges LD50
  78. [78]
    Allometric principles for interspecies extrapolation in toxicological ...
    For LD(50) values, agreement was poor for both allometric concepts. Recently reported concordance of LD(50) species differences with body weight scaling could ...
  79. [79]
    Allometric principles for interspecies extrapolation in toxicological ...
    Four types of data (toxicokinetic data of pharmaceuticals from six species including humans, LD50 values from eight animal species, long-term NOAEL values of ...
  80. [80]
    [PDF] Practical Considerations in Dose Extrapolation from Animals to ...
    The extrapolation of deposited dose in the lungs from laboratory animals to humans is challenging because of genetic, anatomical, physiological, pharma- ...
  81. [81]
    Pre-clinical animal models are poor predictors of human toxicities in ...
    Sep 1, 2020 · Overall, animal toxicity did not show strong correlation with human toxicity, with a median PPV of 0.65 and NPV of 0.50.Data Collection · Drug And Data... · Ethics DeclarationsMissing: LD50 | Show results with:LD50<|separator|>
  82. [82]
    [PDF] Acute Toxicity Testing Without Animals - WBI Studies Repository
    For testing by the oral route, the LD50 method has been deleted from OECD test guidelines in favour of protocols using fewer animals. These include the Fixed ...<|separator|>
  83. [83]
    Values and Limitations of Animal Toxicity Data - NCBI - NIH
    The doses administered to humans would be relatively low, but they should produce changes in sensitive adaptive effects, or biomarkers. Pharmacokinetic (PK), ...
  84. [84]
    Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
    Two critical “wrong” decisions regarding animal tests of human pharmaceuticals are 1) falsely identifying a toxic drug as “safe” and 2) falsely labeling a ...Missing: LD50 | Show results with:LD50
  85. [85]
    Quantitative in vitro to in vivo extrapolation for human toxicology and ...
    Jan 6, 2024 · Traditional animal testing for toxicity is expensive, time consuming, ethically questioned, sometimes inaccurate because of the necessity to ...<|separator|>
  86. [86]
    USDA Pain & Distress Categories | UK Research
    Examples of category E procedures are lethal dose studies (e.g. LD50 studies) that allow animals to die without intervention, pain studies that would not be ...Missing: details | Show results with:details
  87. [87]
    16 CFR 1500.232 -- Statement on animal testing policy. - eCFR
    This procedure reduces the number of animals tested from the 80 to 100 animals involved in a full LD50 test to, typically, 10 to 20 rats per product.
  88. [88]
    [PDF] 3R Principle and Alternative Toxicity Testing Methods
    After the deletion of LD50, three alternative animal tests, the “Fixed Dose Procedure (FDP)”, the “Acute. Toxic Class Method (ATC)” and the “Up and. Down ...
  89. [89]
    [PDF] Guidance Document on the Recognition, Assessment and Use of ...
    A humane endpoint can be defined as the earliest indicator in an animal experiment of severe pain, severe distress, suffering, or impending death. 10. The ...
  90. [90]
    [PDF] OECD Test Guideline 423 - National Toxicology Program
    Dec 17, 2001 · OECD Guideline 423 is a method for testing acute oral toxicity of chemicals using a stepwise procedure with 3 animals per step, using fixed ...
  91. [91]
    In vitro cytotoxicity testing for prediction of acute human toxicity
    This study was designed to compare the cytotoxic concentrations of chemicals, determined with three independent in vitro cytotoxicity testing protocols, ...
  92. [92]
    Comparison of in vivo acute lethal potency and in vitro cytotoxicity of ...
    The results show that an accurate in vivo LD50 dose could be predicted from in vitro data for at least 75% of the selected compounds. It is hoped that this ...
  93. [93]
    Prediction of chemical-induced acute toxicity using in vitro assay ...
    In this study, we assessed the utility of Tox21 assay data in comparison with chemical structure information in predicting acute systemic toxicity.
  94. [94]
    Determination of the Starting Dose for Acute Oral Toxicity (LD50 ...
    Aug 7, 2025 · In the present study, we have used the RC and its IC50/LD50 regression model to predict the LD50 values from cytotoxicity data for nine ...
  95. [95]
    SAR and QSAR modeling of a large collection of LD50 rat acute oral ...
    Aug 30, 2019 · A large database of rat acute oral LD50 data, with the aim of supporting the development of new computational models for predicting five regulatory relevant ...
  96. [96]
    Toxicity Estimation Software Tool (TEST) | US EPA
    QSARs are mathematical models used to predict measures of toxicity from the physical characteristics of the structure of chemicals (known as molecular ...
  97. [97]
    [PDF] An investigation into the use of computational and in vitro methods ...
    Among the QSAR models, the best performing models were ToxSuite and TEST, with correlation coefficients of approximately 80% in LD50 prediction, and accuracies ...<|separator|>
  98. [98]
    QSAR Classification Modeling Using Machine Learning with a ...
    Dec 11, 2024 · This study introduces an innovative computational approach using hybrid machine learning models to predict toxicity across eight critical end points.
  99. [99]
    The prediction of acute toxicity (LD50) for organophosphorus-based ...
    Dec 5, 2023 · The present study explains the acute toxicity of the examined V-series nerve agents (n = 9) using QSAR models.
  100. [100]
    Conservative consensus QSAR approach for the prediction of rat ...
    This study evaluated the performance of TEST, CATMoS and VEGA models for prediction of oral rat LD50, both individually and in consensus, across a dataset of ...
  101. [101]
    Machine Learning Toxicity Prediction: Latest Advances by Toxicity ...
    Both regression and multiclassification models were developed. The regression models allow quantitative prediction of the LD50 values for compounds reflecting ...
  102. [102]
    Review of machine learning and deep learning models for toxicity ...
    This review summarizes the machine learning- and deep learning-based toxicity prediction models developed in recent years.
  103. [103]
    Predicting Dose-Range Chemical Toxicity using Novel Hybrid Deep ...
    Nov 18, 2022 · We present a novel hybrid neural network (HNN) deep learning method, called HNN-Tox, to predict chemical toxicity at different doses.Missing: lethal | Show results with:lethal
  104. [104]
    ProTox-3.0 - Prediction of TOXicity of chemicals
    The LD50 is the median lethal dose meaning the dose at which 50% of test subjects die upon exposure to a compound.Models · Tox-Prediction · FAQ · Links
  105. [105]
    Recent advances in AI-based toxicity prediction for drug discovery
    This review provides an in-depth examination of AI-driven toxicity prediction, emphasizing its transformative impact on drug discovery.